Abstract
Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patients age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving the survival and quality of life in patients with advanced prostate cancer. Apoptosis as a genetically regulated process has a critical endpoint that coincides with the therapeutic goal of successful treatment of androgen-dependent and androgen-independent prostate cancer. Opportunities to alter the apoptotic threshold of prostate cancer cells using antisense technology and gene therapy certainly exist, but the scope and extent of their applicability and action depends upon research delineating the many subtleties within the apoptotic pathway. Most epithelial and endothelial cells undergo apoptosis when they loose contact with the extracellular matrix (ECM), via the phenomenon of anoikis. Signaling interaction between growth factor apoptosis-signaling pathways and cellular effectors of anoikis potential and tumor vascularity provides a new molecular basis for optimizing combination approaches for the effective treatment of advanced prostate cancer. Agents that induce epithelial or endothelial cell apoptosis by antagonizing integrin binding are considered for cancer therapy via their ability to inhibit tumor vascularization. This review summarizes the current knowledge of the therapeutic benefit of apoptosis induction within the context of tumor neovascularization inhibition, and provides an insight into the consequences of anoikis induction (by different agents) in targeting angiogenesis in prostate cancer cells.
Keywords: Apoptosis, anoikis, angiogenesis, neovascularization
Current Cancer Drug Targets
Title: Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Volume: 4 Issue: 1
Author(s): Jason B. Garrison and Natasha Kyprianou
Affiliation:
Keywords: Apoptosis, anoikis, angiogenesis, neovascularization
Abstract: Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patients age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving the survival and quality of life in patients with advanced prostate cancer. Apoptosis as a genetically regulated process has a critical endpoint that coincides with the therapeutic goal of successful treatment of androgen-dependent and androgen-independent prostate cancer. Opportunities to alter the apoptotic threshold of prostate cancer cells using antisense technology and gene therapy certainly exist, but the scope and extent of their applicability and action depends upon research delineating the many subtleties within the apoptotic pathway. Most epithelial and endothelial cells undergo apoptosis when they loose contact with the extracellular matrix (ECM), via the phenomenon of anoikis. Signaling interaction between growth factor apoptosis-signaling pathways and cellular effectors of anoikis potential and tumor vascularity provides a new molecular basis for optimizing combination approaches for the effective treatment of advanced prostate cancer. Agents that induce epithelial or endothelial cell apoptosis by antagonizing integrin binding are considered for cancer therapy via their ability to inhibit tumor vascularization. This review summarizes the current knowledge of the therapeutic benefit of apoptosis induction within the context of tumor neovascularization inhibition, and provides an insight into the consequences of anoikis induction (by different agents) in targeting angiogenesis in prostate cancer cells.
Export Options
About this article
Cite this article as:
Garrison B. Jason and Kyprianou Natasha, Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy, Current Cancer Drug Targets 2004; 4 (1) . https://dx.doi.org/10.2174/1568009043481623
DOI https://dx.doi.org/10.2174/1568009043481623 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hetero-Oligomerization of Chemokine Receptors: Diversity and Relevance for Function
Current Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets AAV-Mediated Gene Supply for Treatment of Degenerative and Neovascular Retinal Diseases
Current Gene Therapy Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Advances in Quantitative Mass Spectrometry Analysis: Weighing in on Isotope Coding and Label-Free Approaches for Expression and Functional Proteomics
Current Analytical Chemistry Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Entosis: Cell-in-Cell Formation that Kills Through Entotic Cell Death
Current Molecular Medicine Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Reviews on Recent Clinical Trials Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Biologically Active Synthetic Anionophores
Current Organic Chemistry Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology The Effects of Kisspeptin in Human Reproductive Function – Therapeutic Implications
Current Drug Targets Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy
Current Molecular Imaging (Discontinued) Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology